This inventor holds 1 USPTO granted patent. Top assignee: Actelion Pharmaceuticals Ltd. Active years: 2025.
Company Filing History:
Years Active: 2025
Title: Michael Keating: Innovator in Pulmonary Arterial Hypertension Treatment
Introduction
Michael Keating is a notable inventor based in Fairview, NC (US). He has made significant contributions to the field of medicine, particularly in the treatment of pulmonary arterial hypertension. His innovative approach has led to the development of methods that enhance patient care and treatment efficacy.
Latest Patents
Michael Keating holds a patent for "Transitioning patients treated for pulmonary arterial hypertension to selexipag." This patent outlines methods for transitioning patients who are currently being treated with a non-selexipag prostacyclin pathway agent to selexipag, which is crucial for improving patient outcomes in this challenging condition. He has 1 patent to his name.
Career Highlights
Keating is associated with Actelion Pharmaceuticals Ltd., a company known for its focus on innovative treatments for pulmonary diseases. His work at Actelion has positioned him as a key player in the development of therapies that address complex health issues.
Collaborations
Throughout his career, Michael has collaborated with talented professionals, including Carol Zhao and Wade Benton. These partnerships have fostered an environment of innovation and have contributed to the advancement of treatment methodologies in the pharmaceutical industry.
Conclusion
Michael Keating's contributions to the field of pulmonary arterial hypertension treatment exemplify the impact of innovation in healthcare. His dedication to improving patient care through his patented methods highlights the importance of ongoing research and development in medicine.